{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:54:05Z","timestamp":1789494845119,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012095","name":"Les 111 des Arts","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012095","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019329","name":"Emerson Collective","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006458","name":"Children's Hospital of Philadelphia","doi-asserted-by":"publisher","award":["GSE309882"],"award-info":[{"award-number":["GSE309882"]}],"id":[{"id":"10.13039\/100006458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.exphem.2025.105268","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:38:11Z","timestamp":1759149491000},"page":"105268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Upfront menin-inhibitor resistance in multiply pretreated leukemias"],"prefix":"10.1016","volume":"153","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0621-7940","authenticated-orcid":false,"given":"Leila","family":"Mahdavi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Alikarami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6838-3417","authenticated-orcid":false,"given":"Haley","family":"Goodrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Lenard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9941-1920","authenticated-orcid":false,"given":"Simone S.","family":"Riedel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-5728","authenticated-orcid":false,"given":"Clara","family":"Libbrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Bowser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Tasian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine D.","family":"Falkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan","family":"Manning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Skuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-3735","authenticated-orcid":false,"given":"Martin P.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Wertheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2708-887X","authenticated-orcid":false,"given":"Sheng F.","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"McGeehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sixiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8427-6316","authenticated-orcid":false,"given":"Junwei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo M.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-356X","authenticated-orcid":false,"given":"Kathrin M.","family":"Bernt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2025.105268_bib0001","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/leu.2009.33","article-title":"New insights to the MLL recombinome of acute leukemias","volume":"23","author":"Meyer","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105268_bib0002","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105268_bib0003","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1200\/JCO.20.03048","article-title":"Gemtuzumab ozogamicin improves event-free survival and reduces relapse in pediatric KMT2A-rearranged AML: results from the phase III children's oncology group trial AAML0531","volume":"39","author":"Pollard","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.105268_bib0004","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.exphem.2025.105268_bib0005","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1182\/blood-2002-10-3221","article-title":"Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation","volume":"102","author":"Ferrando","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105268_bib0006","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/s41375-021-01177-6","article-title":"FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: children's oncology group trial AALL0631","volume":"35","author":"Brown","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105268_bib0007","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1200\/JCO.19.00261","article-title":"Outcome of infants younger than 1 year with acute lymphoblastic leukemia treated with the interfant-06 protocol: results from an international phase III randomized study","volume":"37","author":"Pieters","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.exphem.2025.105268_bib0008","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1182\/bloodadvances.2021004580","article-title":"Outcomes of acute lymphoblastic leukemia with KMT2A (MLL) rearrangement: the MD Anderson experience","volume":"5","author":"Richard-Carpentier","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.exphem.2025.105268_bib0009","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/leu.2015.144","article-title":"Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner","volume":"30","author":"He","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105268_bib0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccell.2019.11.001","article-title":"A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia","volume":"36","author":"Krivtsov","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.105268_bib0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/nchembio.773","article-title":"Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia","volume":"8","author":"Grembecka","year":"2012","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.exphem.2025.105268_bib0012","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.exphem.2025.105268_bib0013","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ccell.2015.02.016","article-title":"Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo","volume":"27","author":"Borkin","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.exphem.2025.105268_bib0014","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2Arearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105268_bib0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cell.2005.09.025","article-title":"The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis","volume":"123","author":"Yokoyama","year":"2005","journal-title":"Cell"},{"key":"10.1016\/j.exphem.2025.105268_bib0016","doi-asserted-by":"crossref","first-page":"E439","DOI":"10.1002\/ajh.26713","article-title":"CD19-directed immunotherapy use in KMT2A-rearranged acute leukemia: a case report and literature review of increased lymphoid to myeloid lineage switch","volume":"97","author":"Lee","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2025.105268_bib0017","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105268_bib0018","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41408-021-00603-3","article-title":"Effective menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c)","volume":"12","author":"Fiskus","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.exphem.2025.105268_bib0019","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1038\/s41375-022-01707-w","article-title":"Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1","volume":"36","author":"Fiskus","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2025.105268_bib0020","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/onc.2012.110","article-title":"The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia","volume":"32","author":"Shi","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2025.105268_bib0021","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2007-09-113597","article-title":"HOXA9 is required for survival in human MLL-rearranged acute leukemias","volume":"113","author":"Faber","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2025.105268_bib0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1189\/jlb.0206112","article-title":"Genetic regulators of myelopoiesis and leukemic signaling identified by gene profiling and linear modeling","volume":"80","author":"Brown","year":"2006","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.exphem.2025.105268_bib0023","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2159-8290.CD-22-0416","article-title":"A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition","volume":"13","author":"Soto-Feliciano","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.exphem.2025.105268_bib0024","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1038\/onc.2008.213","article-title":"Critical pathways in cellular senescence and immortalization revealed by gene expression profiling","volume":"27","author":"Fridman","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.exphem.2025.105268_bib0025","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2643-3230.BCD-21-0160","article-title":"Integrated genomic analysis identifies UBTF tandem duplications as a recurrent lesion in pediatric acute myeloid leukemia","volume":"3","author":"Umeda","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.exphem.2025.105268_bib0026","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41586-023-05812-3","article-title":"The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia","volume":"615","author":"Issa","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.exphem.2025.105268_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108751","article-title":"Kmt2c mutations enhance HSC self-renewal capacity and convey a selective advantage after chemotherapy","volume":"34","author":"Chen","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.exphem.2025.105268_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01379-3","article-title":"Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences","volume":"23","author":"Priedigkeit","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.exphem.2025.105268_bib0029","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1038\/s41375-019-0402-3","article-title":"Genetic mechanisms of primary chemotherapy resistance in pediatric acute myeloid leukemia","volume":"33","author":"McNeer","year":"2019","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25005570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X25005570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:10:30Z","timestamp":1773814230000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X25005570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":29,"alternative-id":["S0301472X25005570"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2025.105268","relation":{},"ISSN":["0301-472X"],"issn-type":[{"value":"0301-472X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Upfront menin-inhibitor resistance in multiply pretreated leukemias","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2025.105268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Experimental Hematology.","name":"copyright","label":"Copyright"}],"article-number":"105268"}}